Providing a Potent, Multi-Pronged Attack on Cancerous Cells

Treatments that Inhibit Tumor Growth and Metastasis

Our focus is on creating an anti-cancer product that is effective in treating cancer, and which is sufficiently well tolerated to be suitable for chronic, long-term use in patients with diagnosed cancer, and potentially in the longer term in patients at high risk of developing cancer.

Treatments that Inhibit Tumor Growth and Metastasis
Drug Pipeline
Research Screening Preclinical Phase 1 Phase 2 Phase 3
PRP
Research Phase complete
Screening Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
  • 14 day Non GLP dose dose range finding study in rats
  • 28 day GLP toxicology study in rats
  • Bioanalytical assay method development for quantification of PRP in animal and human serum and plasma samples
  • GMP production of PRP for Phase I patient trials
POP1
Research Phase in progress
Screening Phase not started
Preclinical Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
  • Elucidation of molecular target of proenzymes
  • New compound screening
Play Video

A New Frontier In Cancer Therapy

Watch how Propanc is pioneering a new approach to cancer therapy

Our Lead Product: PRP

PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the main cause of patient death from cancer. It’s a novel, patented, formulation consisting of two proenzymes mixed in a synergetic ratio.

How PRP Stands Out

Technology Based on Pancreatic Enzyme Therapy

Pancreatic Enzyme Therapy uses natural elements within our organism that could help us treat cancer.

How Our Technology Works

Meeting Global Demand for Effective, Safe and Easy to Administer Cancer Treatments

Cancer is the leading cause of death worldwide, accounting for 7.6 million deaths in 2008 (source).

Supplying a Market Need